Home / Going-concern warnings / Dermata Therapeutics, Inc.
Filed 2025-05-14 路 Form 10-Q 路 Accession 0001641172-25-010111 nano
Price before filing: $7.8 (2025-05-13 close, split/dividend-adjusted)
Market cap at flag: $8.0M (2025-05-14) 路 Latest: $3.5M (2026-10-16)
| Window | DRMA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -8.7% | +1.7% | -10.5% | 2025-06-13 |
| 90 days | -21.7% | +9.8% | -31.5% | 2025-08-12 |
| 180 days | -58.7% | +16.8% | -75.5% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These factors raise substantial doubt about the Company's ability to continue as a going concern for the one-year period following the date that these financial statements were issued."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure; also within 90 days: Auditor change
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.